Sempra (SRE) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
Achieved record adjusted EPS of $4.69 for 2025, at the high end of guidance, driven by strong execution of value creation initiatives, robust utility investments, and successful asset sales unlocking significant equity value.
Announced a new $65 billion capital plan for 2026-2030, a 17% increase over the prior plan, with 95% targeted for utility investments, especially in Texas and California.
Completed major transactions, including the sale of a 45% stake in Sempra Infrastructure Partners for $10 billion and the agreement to sell Ecogas for $500 million, supporting capital recycling.
Invested $13 billion in 2025, prioritizing utility investments and improved returns, increasing rate base from $50 billion to $57 billion and declaring $1.7 billion in common dividends.
Focused on cost reduction, organizational efficiency, operational excellence, and wildfire risk mitigation.
Financial highlights
Full year 2025 adjusted earnings: $3.07 billion ($4.69/share), up from $2.97 billion ($4.65/share) in 2024; GAAP earnings: $1.80 billion ($2.75/share), down from $2.82 billion ($4.42/share) in 2024.
Q4 2025 adjusted earnings: $841 million ($1.28/share) vs. $960 million ($1.50/share) in Q4 2024.
Net income for 2025 was $2.07 billion, down from $3.5 billion in 2024.
Operating cash flow for 2025 was $4.57 billion, compared to $4.91 billion in 2024.
Capital expenditures for 2025 totaled $13 billion, up from $8.2 billion in 2024.
Outlook and guidance
Affirmed 2026 adjusted EPS guidance of $4.80-$5.30 and introduced 2027 guidance of $5.10-$5.70.
Issued 2030 EPS outlook of $6.70-$7.50, reflecting one of the highest projected growth rates in the sector.
Projected 11% five-year CAGR in overall rate base, with Sempra Texas expected to surpass California as the majority of rate base by 2030.
Targeting annual dividend growth of 2%-4% over the plan period, with dividend increased to $2.63/share annualized for 2026.
No need for common equity issuances to fund base capital plan due to improved operating cash flows and capital recycling.
Latest events from Sempra
- Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025